Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial - Lu, Hongzhou; Zhang, George; Mao, John; Chen, Xiaochun; Zhan, Yangqing; Lin, Ling; Zhang, Tianxiang; Tang, Yanan; Lin, Feng; Zhu, Feiyue; Lin, Yuanlong; Zeng, Yiming; et al. (EClinicalMedicine, 2024)
Keywords: 3CL protease; Anti SARS-CoV-2 drug; COVID-19; Internal Medicine; RCT; XBB variants; COVID-19; 3CL protease; RCT; XBB variants; Anti SARS-CoV-2 drug